【癌症】《Lantern: LTRN》宣布「LP-184」獲FDA三項罕見兒童癌症認定

 【癌症】《Lantern: LTRN》宣布「LP-184」獲FDA三項兒科罕見疾病認定，用於治療多種罕見兒童癌症

 文章出處  

Businesswire 

 

 原文標題  

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers 

 

 Twitter  

https://x.com/aimedadviser/status/1838731281586377186 

 

 文章序號  

6329 

 

智醫科學－AI醫療技術、應用與市場動態

Copyright ©2024 智醫科學 MEDai.tw All rights reserved.

The content of this site is intended for healthcare and medical professionals.